Gsk (GLAXF) Amortization (2009 - 2026)

Gsk's Amortization history runs 18 years deep, the most recent figure standing at $2.5 billion for Q1 2026.

• In Q1 2026, Amortization rose 11.09% year-over-year to $2.5 billion; the TTM figure through Mar 2026 stood at $15.9 billion (up 105.6% YoY), while the FY2025 annual figure was $4.2 billion, down 2.79% from the prior year.
• Amortization was $2.5 billion for Q1 2026 at Gsk, down from $8.4 billion in the prior quarter.
• In the past five years, Amortization ranged from a high of $18.3 billion in Q4 2022 to a low of $84.5 million in Q3 2024.
• Historically, Amortization has averaged $5.1 billion across 5 years, with a median of $2.5 billion in 2026.
• The sharpest annual moves came in 2024 and 2025: Amortization slumped 95.65% in 2024, then soared 3325.55% in 2025.
• A 5-year view of Amortization shows it stood at $18.3 billion in 2022, then sank by 64.04% to $6.6 billion in 2023, then tumbled by 42.51% to $3.8 billion in 2024, then jumped by 120.86% to $8.4 billion in 2025, then plunged by 70.36% to $2.5 billion in 2026.
• The last three Amortization figures came in at $2.5 billion (Q1 2026), $8.4 billion (Q4 2025), and $2.9 billion (Q3 2025), per Business Quant data.